Anti-inflammatory Effects in the Upper Airway

Phase III studies in allergic asthma provide the most clinically relevant results since omalizumab was administered subcutaneously at current doses to large numbers of patients with moderate-severe asthma. These more recent stud- 

Displayed values are mean SD. p-values are from Wilcoxon single rank test 

Marcel Dekker, Inc. 270Madison Avenue. New York, New York 10016 

In all three of the pivotal phase III studies, omalizumab was significantly superior to placebo with respect to the percentage reduction in inhaled corticosteroid dose attained and the proportion of patients who achieved steroid reduction or withdrawal. 

AcUvoled monocyte Eosinophils Epithelial cells Dei dhtic celt 

---